<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004358</url>
  </required_header>
  <id_info>
    <org_study_id>199/11925</org_study_id>
    <secondary_id>NU-477</secondary_id>
    <nct_id>NCT00004358</nct_id>
  </id_info>
  <brief_title>Phase II Study of Calcitonin for Tumoral Calcinosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of
      calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact
      parathyroid hormone levels in patients with tumoral calcinosis.

      II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether
      hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.

      IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone
      metabolism in osteopenic patients with tumoral calcinosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin
      every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.

      Patients are followed for disease progression and tumor recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1992</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>9</enrollment>
  <condition>Calcinosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcitonin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Histologically confirmed tumoral calcinosis --Prior/Concurrent
        Therapy-- Prior surgical resection of calcinotic lesion required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig B. Langman</last_name>
    <role>Study Chair</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>rare disease</keyword>
  <keyword>tumoral calcinosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

